Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alcami Expands Highly Potent API Capabilities and Capacity | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alcami Expands Highly Potent API Capabilities and Capacity

Will enhance Germantown, WI, facility to introduce the development and manufacturing of highly potent APIs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alcami has unveiled plans to expand capabilities for development and manufacturing of active pharmaceutical ingredients (APIs) at its Germantown, WI facility.

Alcami plans to invest in 2016 and 2017 toward the enhancement of new and existing kilo labs to introduce the development and manufacturing of highly potent APIs. The two new cGMP, highly potent API (HPAPI) production suites will focus on primary containment technologies with engineering controls designed to meet the established Occupational Exposure Limit (OEL) of minimally 0.03 μg/m3 (SafeBridge Category 3).

The 5,000 square foot renovation will be operational by Q1, 2017. The newly designed space will include up to 150L reactor scale with cryogenic capabilities to service a wide range of complex chemistries.

These advancements follow operational and technology enhancements across development, clinical and commercial manufacturing to increase production capacity by 50%. This positions Alcami’s global API operations—Germantown, WI and Weert, The Netherlands—to meet the increasing demand of new clinical candidates, of which greater than 70% originate from small and mid-size pharma and biotech.

“This investment in highly potent capabilities is consistent with our vision to be a technology leader and address unmet market needs. Alcami is committed to ongoing investments in our people, technology, equipment, and capabilities to enable us to exceed our customers’ needs from preclinical to commercial,” said Ted Dolan, chief operating officer, Alcami.

The Germantown, WI, facility recently completed an FDA General Inspection that resulted in zero 483 observations.

Visit Alcami at Table 62

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics